TEL AVIV, Israel, April 26, 2022 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of Aramchol, a liver targeted, oral, SCD1 modulator, currently in
Phase 3 clinical trial for the treatment of nonalcoholic
steatohepatitis (NASH) and fibrosis announced today that it will
host a conference call and webcast on Monday, May 2, 2022, to provide an update on
current developments with respect to its clinical programs for
Aramchol™ and to discuss financial results for the fourth quarter
and year ended December 31, 2021.
Conference Call & Webcast:
Monday May 2, 2022,
8:30 AM ET
Toll
Free: 1-877-425-9470
Toll/International: 1-201-389-0878
Israel Toll
Free: 1
809 406 247
Conference
ID: 13727793
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1535647&tp_key=893b75d833
Replay Dial-In Numbers
Toll Free:
1-844-512-2921
Toll/International:
1-412-317-6671
Replay Pin
Number: 13727793
Replay Start:
Monday May 2, 2022, 11:30
AM ET
Replay Expiry:
Monday
May 16, 2022, 11:59 PM ET
About Aramchol and Non-alcoholic Steatohepatitis
(NASH)
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, inducing beneficial modulation of
intra-hepatic lipid metabolism. Aramchol's ability to modulate
hepatic lipid metabolism was discovered and validated in animal
models, demonstrating downregulation of the three key pathologies
of NASH: steatosis, inflammation and fibrosis. The effect of
Aramchol on fibrosis is mediated by downregulation of steatosis and
directly on human collagen producing cells. Aramchol has been
granted Fast Track designation status by the FDA for the treatment
of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplant in
the U.S. due to the rise in obesity. NASH is the progressive form
of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a clinical stage drug development
biopharmaceutical company for liver, metabolic and inflammatory
diseases. Our lead compound, Aramchol™, a backbone drug candidate
for the treatment of NASH and fibrosis is currently in a Phase 3
registrational study. We are also collaborating with
the Hebrew University in the development of Amilo-5MER, a
5 amino acid synthetic peptide and recently initiated a first in
human study.
View original
content:https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-fourth-quarter-and-year-end-2021-financial-results-and-provide-business-update-on-monday-may-2-301532959.html
SOURCE Galmed Pharmaceuticals Ltd.